Supplementary Table S2 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer

Sebastian Medina; Naoto Tokuyama; Kamal Hammouda; Tilak Bahadur Pathak; Tuomas K. Mirtti; Pingfu Fu; Shilpa Gupta; Priti Lal; Howard Mark Sandler; Rohann Jonathan Mark Correa; Susan Chafe; Amit Shah; Jason Alexander Efstathiou; Karen Hoffman; Michael Straza; Mark A. Hallman; Richard C. Jordan; Stephanie L. Pugh; Christopher J. Sweeney; Anant Madabhushi

doi:10.1158/1078-0432.31248887

Supplementary Table S2 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer

2026 Open access

Read full text

Authors: Sebastian Medina, Naoto Tokuyama, Kamal Hammouda, Tilak Bahadur Pathak, Tuomas K. Mirtti, Pingfu Fu, Shilpa Gupta, Priti Lal, Howard Mark Sandler, Rohann Jonathan Mark Correa, Susan Chafe, Amit Shah

+8 more

Jason Alexander Efstathiou, Karen Hoffman, Michael Straza, Mark A. Hallman, Richard C. Jordan, Stephanie L. Pugh, Christopher J. Sweeney, Anant Madabhushi

DOI: 10.1158/1078-0432.31248887

Cited by: 0

Abstract

Comparison of baseline clinicopathologic characteristics between included and excluded patients by treatment arm in the CHAARTED trial

Fields of Study & Subjects

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Breast Cancer Treatment Studies

Publication details

Publication date: 4 February 2026